Group 1: Financial Performance and Product Sales - In 2025, the sales revenue of DK185 corneal reshaping lenses accounted for 5.71% of hard lens sales, while scleral lenses accounted for 1.23% [3] - The average price of existing corneal reshaping lenses decreased in 2025, but the overall profit margin for hard lens business declined due to increased sales and management expenses [6] - The revenue from frame glasses and other optical products grew by 19.49%, reflecting the implementation of a comprehensive optical service strategy [8] Group 2: Product Development and Market Strategy - The company is focusing on promoting ultra-high oxygen permeability corneal reshaping lenses and scleral lenses in 2026, with plans to expand the user base by introducing adult corneal reshaping lenses [3] - The company has several products in clinical trials, including the OVCTEK 210FX corneal reshaping lens and a hydrogen peroxide care solution [4] - The company is cautious about expanding optical terminals, prioritizing feasibility assessments and quality [5] Group 3: Investor Relations and Market Outlook - The online meeting on March 30, 2026, included 58 participants from various securities firms and investment institutions [2] - The company is exploring overseas sales through both offline and cross-border e-commerce, with ongoing registration for medical devices in Southeast Asia [9] - The company plans to enhance its product offerings in the eye health sector, including functional soft lenses and high-end soft lens materials [4][7]